Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 0.58 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.52 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10155800 | 0.91 | ADORA2A (0.68) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL10156319 | 0.91 | ADORA2A (0.68) | ADORA2AADORA1ADORA3ADORA2B | |
| Trifluoroacetic Acid SCHEMBL4225494 | 0.89 | ADORA2A (0.73) | ADORA2AADORA1ADORA3ADORA2B | |
| Trifluoroacetic Acid SCHEMBL3907185 | 0.89 | ADORA2A (0.60) | ADORA2AADORA1ADORA3ADORA2B | |
| Trifluoroacetic Acid SCHEMBL4225820 | 0.88 | ADORA2A (0.48) | ADORA2AADORA1ADORA3ADORA2B | |
| Trifluoroacetic Acid SCHEMBL3916265 | 0.87 | ADORA2A (0.47) | ADORA2AADORA1ADORA3ADORA2B | |
| Trifluoroacetic Acid SCHEMBL4225568 | 0.87 | ADORA2A (0.62) | ADORA2AADORA1ADORA3ADORA2B | |
| SCHEMBL10156090 | 0.87 | ADORA2A (0.64) | ADORA2AADORA1ADORA3ADORA2B | |
| Trifluoroacetic Acid SCHEMBL4221929 | 0.87 | ADORA2A (0.59) | ADORA2AADORA1ADORA3ADORA2B | |
| Trifluoroacetic Acid SCHEMBL4215954 | 0.87 | ADORA2A (0.59) | ADORA2AADORA1ADORA3ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090240045-A1 | Organic Compounds | NOVARTIS AG | 2009-09-24 | — | — | US | claimed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | claimed |
| EP-1861412-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | Novartis AG (CH) | 2007-12-05 | — | — | EP | claimed |
| WO-2006097260-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | claimed |
| US-8193164-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100190784-A1 | Organic Compounds | NOVARTIS AG | 2010-07-29 | — | — | US | disclosed |
| US-20090240045-A1 | Organic Compounds | NOVARTIS AG | 2009-09-24 | — | — | US | disclosed |
| US-20080242683-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | disclosed |
| EP-1861412-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | Novartis AG (CH) | 2007-12-05 | — | — | EP | disclosed |
| WO-2006097260-A1 | ADENOSINE DERIVATIVES HAVING A2A RECEPTOR ACTIVITY | NOVARTIS AG (CH) | 2006-09-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242683-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | ADORA2A 1/4885ADORA1 3/4885ADORA3 2/4885 |
| US-20090240045-A1 | Organic Compounds | CYP3A43, CYP3A4, SLCO1B3 | ADORA2A 2314/4885ADORA1 838/4885ADORA3 545/4885 |
| US-20100190784-A1 | Organic Compounds | CYP1B1, POLR2A, CYP1A1 | ADORA2A 1137/4885ADORA1 697/4885ADORA3 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.